Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

JAMA: The Journal of the American Medical Association

Volumn 257, Issue 23, 1987, Pages 3233-3240

  Blankenhorn, David H ^a   Nessim, Sharon A ^b   Johnson, Ruth L ^c   Sanmarco, Miguel E ^a   Azen, Stanley P ^b   Cashin Hemphill, Linda ^a  

^a Department of Medicine ^*

^b Department of Preventive Medicine ^*

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; NICOTINIC ACID; PLACEBO;

ADULT; ADVERSE DRUG REACTION; ANGIOGRAPHY; BLOOD AND HEMOPOIETIC SYSTEM; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DIAGNOSIS; DRUG EFFICACY; DRUG MIXTURE; DRUG THERAPY; ETIOLOGY; HEART; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THERAPY;

ADULT; CLINICAL TRIALS; COLESTIPOL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; GRAFT OCCLUSION, VASCULAR; HUMANS; LIPIDS; MALE; MIDDLE AGED; NIACIN; POLYAMINES; RANDOM ALLOCATION;

EID: 84948007950     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1987.03390230069027     Document Type: Article

References (30)

1. Keys A (ed): Coronary heart disease in seven countries. Circulation 1970;41(suppl 1):I-1-I-211.
2. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
3. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
4. Malinow MR, Blaton V: Regression of atherosclerotic lesions. Arteriosclerosis 1984;4:292-295.
5. Brensike JF, Levy RI, Kelsey SF, et al.: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-324.
6. Cohn K, Sakai FJ, Langston MF Jr: Effect of clofibrate on progression of coronary disease: A prospective angiographic study in man. Am Heart J 1975;89:591-598.
7. Arntzenius AC, Kromhout D, Barth JD, et al.: Diet, lipoproteins, and the progression of coronary atherosclerosis: The Leiden Intervention Trial. N Engl J Med 1985;312:805-811.
8. Nikkila EA, Viikinkoski P, Valle M, et al.: Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: A seven year prospective angiographic study. Br Med J 1984; 289:220-223.
9. Nash DT, Gensini G, Esente P: Effect of lipidlowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol 1982;2: 43-55.
10. Kuo PT, Hayase K, Kostis JB, et al.: Use of combined diet and colestipol in long-term (7-7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation 1979;59:199-211.
11. Duffield RG, Lewis B, Miller NE, et al.: Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: A randomised controlled trial. Lancet 1983;2:639-642.
12. Sherwin R, Kaelber CT, Kezdi P, et al.: The Multiple Risk Factor Intervention Trial (MRFIT) II: The development of the protocol. Prev Med 1981;10:402-425.
13. Brooks SH, Blankenhorn DH, Chin HP, et al.: Design of human atherosclerosis studies by serial angiography. J Chronic Dis 1980;33:347-357.
14. Blankenhorn DH, Brooks SH: Angiographic trials of lipid-lowering therapy. Arteriosclerosis 1981;1:242-249.
15. Blankenhorn DH, Johnson RL, Nessim SA, et al.: The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, methods, and baseline results. Controlled Clin Trials, in press.
16. Keys A, Anderson JT, Grande F: Serum cholesterol response to changes in the diet: I. Iodine value of dietary fat versus 2S-P. Metabolism 1965; 14:747-758.
17. Burstein M, Samaille J: Sur un dosage rapide du cholesterol lie aux a et au b-lipoproteines du serum. Clin Chim Acta 1960;5:609.
18. Lipid Research Clinics Program: The Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, publication NIH 75-628. Bethesda, Md, National Institutes of Health, 1974.
19. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
20. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 1982;248:1465-1477.
21. Johnson RL, Selzer R, Blankenhorn DH, et al.: Nutrient Analysis System—a computerized seven-day food record system. J Am Diet Assoc 1983;83: 667-671.
22. SAS User’s Guide: Statistics, ed 5. Cray, NC, SAS Institute Inc, 1985.
23. Siegel S: Nonparametric Statistics for the Behavioral Sciences. New York, McGraw-Hill International Book Co, 1956.
24. Massey FJ Jr, Bernstein GS, O’Fallon WM, et al.: Vasectomy and health: Results from a large cohort study. JAMA 1984;252:1023-1029.
25. Loop FD, Cosgrove DM: Repeat coronary bypass surgery: Selection of cases, surgical risks, and long-term outlook. Mod Concepts Cardiovasc Dis 1986;55:31-36.
26. Moise A, Bourassa MG, Theroux P, et al.: Prognostic significance of progression of coronary artery disease. Am J Cardiol 1985;55:941-946.
27. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
28. Canner PL, Berg KG, Wegner NK, et al.: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
29. Detre KM, Levy RI, Kelsey SF, et al.: Secondary prevention and lipid lowering: Results and implications. Am Heart J 1985;110:1123-1127.
30. Lowering blood cholesterol to prevent heart disease, CONSENSUS CONFERENCE. JAMA 1985; 253:2080-2086.